Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer
November 01 2019 - 8:01AM
Business Wire
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine
company, announced today the appointment of Sung Lee as Executive
Vice President and Chief Financial Officer, effective October 31,
2019. Mr. Lee oversees finance, facilities and information
technology functions for Sangamo and reports to the Chief Executive
Officer.
“I am excited to welcome Sung to the leadership team and believe
that his exceptional track record of improving operational
performance, leading large teams, and communicating with investors,
as well as his deep experience and success in financial planning
and analysis, will have a significant impact on Sangamo as we
continue to grow,” said Sandy Macrae, Sangamo's Chief Executive
Officer.
Mr. Lee joins Sangamo from Gilead Sciences, where he spent
nearly 14 years, most recently as Senior Vice President leading the
financial planning & analysis (FP&A) and investor relations
functions. In this dual capacity, he managed the global planning
and budgeting process, drove process improvement, and managed all
aspects of communications to the investor community. Prior to this
role, Mr. Lee held roles of increasing responsibility at Gilead,
including Head of Europe Finance and Head of R&D FP&A.
Mr. Lee received a B.A. in Economics from University of
California, Irvine, and a M.B.T. from University of Southern
California.
About Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking
science into genomic medicines with the potential to transform
patients’ lives using gene therapy, ex vivo gene-edited cell
therapy, and in vivo genome editing and gene regulation. For more
information about Sangamo, visit www.sangamo.com
Forward-Looking Statements
This press release contains forward-looking statements regarding
Sangamo's current expectations. These forward-looking statements
include, without limitation, references to Sangamo's anticipated
growth as a clinical stage development company and into
commercialization. These statements are not guarantees of future
performance and are subject to certain risks, uncertainties and
assumptions that are difficult to predict. Actual results may
differ from those projected in forward-looking statements due to
risks and uncertainties that exist in Sangamo's operations and
business environments. These risks and uncertainties are described
more fully in Sangamo's Annual and Quarterly Reports as filed with
the Securities and Exchange Commission. Forward-looking statements
contained in this press release are made as of this date, and
Sangamo undertakes no duty to update such information except as
required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191101005100/en/
Investor Relations – Global McDavid
Stilwell 510-970-6000, x219 mstilwell@sangamo.com
Media Inquiries – Global Aron
Feingold 510-970-6000, x421 afeingold@sangamo.com
Investor Relations and Media Inquiries –
European Union & United Kingdom Caroline Courme 33 4 97
21 27 27 ccourme@sangamo.com
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Apr 2023 to Apr 2024